Clinical trial
The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or…
NCT00001074 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00001074 |
|---|---|
| Title | The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients |
| Official title | A Phase I/II Dosing Study of the Safety and Antiretroviral Activity of Hydroxyurea Alone and in Combination With ddI Compared With ddI Alone in Subjects With HIV Infection |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Hydroxyurea, Didanosine |
| Enrollment | 140 |
| Completion | Jan 1, 2000 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 1, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: